Inhibikase Therapeutics Files Proxy Statement Supplement
Ticker: IKT · Form: DEFA14A · Filed: Jun 12, 2025 · CIK: 1750149
Sentiment: neutral
Topics: proxy-statement, sec-filing, supplemental-filing
Related Tickers: INHI
TL;DR
INHI filed proxy docs, no fee. Shareholders get more info.
AI Summary
Inhibikase Therapeutics, Inc. filed a Definitive Additional Materials filing (DEFA14A) on June 12, 2025. This filing supplements their proxy statement, indicating it's not a preliminary document and no fee was required for this submission. The company is based in Wilmington, DE.
Why It Matters
This filing provides additional information to shareholders regarding matters to be voted on at a company meeting, ensuring transparency and informed decision-making.
Risk Assessment
Risk Level: low — This is a routine SEC filing (DEFA14A) supplementing a proxy statement, not indicating any immediate financial distress or significant corporate action.
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- 0001193125-25-139929 (filing_id) — Accession Number
- 20250612 (date) — Filing Date
- 1000 N. West Street, Suite 1200 Wilmington, DE 19801 (address) — Company Business Address
FAQ
What type of SEC filing is this?
This is a DEFA14A, which is a Definitive Additional Materials filing supplementing a proxy statement.
Who is the filing company?
The filing company is Inhibikase Therapeutics, Inc.
When was this filing submitted?
The filing was submitted on June 12, 2025.
Was there a fee required for this filing?
No, the filing indicates that no fee was required.
What is the company's primary business sector?
The company's Standard Industrial Classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 12, 2025 regarding Inhibikase Therapeutics, Inc. (IKT).